{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.41","upperLimit":"1.64","value":"1.51"},{"groupId":"OG001","lowerLimit":"1.61","upperLimit":"2.79","value":"2.00"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"387"},{"groupId":"OG001","value":"381"}],"units":"Participants"}],"dispersionType":"95% Confidence Interval","groups":[{"description":"Panobinostat was given 20 mg hard gelatin capsules . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV)injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG000","title":"Panobinostat + Bortezomib"},{"description":"Placebo was given as a hard gelatin capsule in the image of Panobinostat . Bortezomib was given at 1.3 mg/m2 as a 3 to 5 second bolus intravenous (IV) injection. Dexamethasone was given as an oral dose of 20 mg/day.","id":"OG001","title":"Placebo + Bortezomib"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"45 months","title":"Time to Response Per Investigator Assessment (mEBMT Criteria) of Response Patients Treated With Panobinostat in Combination With Bortezomib and Dexamethasone vs. Patients Treated by Placebo in Combination With Bortezomib and Dexamethasone.","type":"SECONDARY","unitOfMeasure":"time to response in months"}